Abstract | OBJECTIVES: METHODS: A total of 177 male patients with nocturia were included in the present study and randomized to morning or evening dosing of naftopidil. The International Prostate Symptom Score, quality of life index and nocturia quality of life index were compared between the two study groups at 12 weeks. RESULTS: A total of 143 patients (morning group: n = 70, evening group: n = 73) were analyzed as a result of the dropout of 34 patients because of failure to give consent, adverse events and failure to attend. Nocturia, quality of life index and nocturia quality of life index at 12 weeks were significantly better in the evening group compared with the morning group. In a multivariate model, both the dosing time of naftopidil and the initial nocturia quality of life index were significantly associated with change in nocturia quality of life index. CONCLUSIONS:
|
Authors | Tomoaki Tanaka, Katsuyuki Kuratsukuri, Rikio Yoshimura, Takahisa Adachi, Tetsuo Yamaguchi, Tetsuji Ohmachi, Shinji Yamamoto, Takahiro Nakamura, Satoshi Tamada, Tatsuya Nakatani |
Journal | International journal of urology : official journal of the Japanese Urological Association
(Int J Urol)
Vol. 22
Issue 3
Pg. 317-21
(Mar 2015)
ISSN: 1442-2042 [Electronic] Australia |
PMID | 25421868
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial)
|
Copyright | © 2014 The Japanese Urological Association. |
Chemical References |
- Adrenergic alpha-Antagonists
- Naphthalenes
- Piperazines
- naftopidil
|
Topics |
- Adrenergic alpha-Antagonists
(administration & dosage)
- Aged
- Aged, 80 and over
- Humans
- Male
- Middle Aged
- Multivariate Analysis
- Naphthalenes
(administration & dosage)
- Nocturia
(drug therapy)
- Piperazines
(administration & dosage)
- Prostatic Hyperplasia
(complications)
- Quality of Life
- Time Factors
- Treatment Outcome
- Urodynamics
|